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A B S T R A C T
Angiotensin converting enzyme (ACE) inhibitors provide well known cardiorenal-protective benefits added to antihy-
pertensive effects in chronic renal disease. These agents are underused in management of patients receiving hemodialy-
sis (HD) because of common concern of hyperkalemia. However, few studies have investigated effect of renin angiotensin
aldosterone system (RAAS) blockade on serum potassium in hemodialysis patients. We assessed the safety of ramipril in
patients on maintenance HD. We enrolled 28 adult end stage renal disease (ESRD) patients treated by maintenance HD
and prescribed them ramipril in doses of 1.25 to 5 mg per day. They underwent serum potassium concentration measure-
ments before ramipril introduction and in 1 to 3 months afterwards. No significant increase in kalemia was found. Re-
sults of our study encourage the use of ACE inhibitors in chronically hemodialyzed patients, but close potassium moni-
toring is mandatory.
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Introduction
Chronic kidney disease accelerates atherosclerosis,
myocardial disease, and valvular disease and promotes
cardiac arrhythmias. These factors present strong risk
for cardiovascular mortality, which is leading cause of
death among these patients. Retrospective studies have
identified renal dysfunction as the most significant prog-
nostic factor for long-term mortality1 and patients with
chronic renal failure have the highest mortality rate in
chronic diseasepopulation2. Also, multiple studies in pa-
tients with class II and III of heart failure have shown de-
creased survival related to the renal impairment3. Dete-
rioration of renal function is mediated by glomerular
capillary hypertension, and ACE (angiotensin converting
enzyme) inhibitors, which selectively lower glomerular
pressure, should be most effective in inhibiting progres-
sion to ESRD (end stage renal disease). Patients with
ESRD have worse outcome considering cardiac death
even in comparison with diabetic patients. Treating a pa-
tient with ESRD presents a challenge to a clinician and
ACE inhibitors are a treatment option. Hyperactivation
of the RAAS (renin angiotensin aldosteron system) is a
target for therapy in ESRD and ACE inhibitors have
been proven to reduce LVH and possibly improve sur-
vival4. A retrospective study found that only approxi-
mately 20 percent of patients with ESRD and CAD (coro-
nary artery disease) receive ACE inhibitors1.
ACE inhibitors are officially contraindicated in severe
renal failure and common concern is hyperkalemia. The
mechanisms responsible for potassium homeostasis are
renal, gastrointestinal and skin potassium excretion. The
most important mechanism is the renal excretion and
the major site of renal regulation of potassium excretion
occurs in the distal tubules and collecting ducts. The
stimulation of potassium secretion is related to the abil-
ity of aldosteron to stimulate sodium potassium ATPase
(adenosine triphosphatase) activity in cells of distal tu-
bule. ACE inhibition is associated with aldosteron reduc-
tion and has potential indirect natriuretic and potassium
retaining effects. Urine flow rate increases urinary po-
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tassium excretion and hyperkalemia is a common com-
plication of oliguric renal failure and urinary tract obstru-
ction5. It is less commonly associated with non-oliguric
renal failure and is rarely associated with prerenal azo-
temia unless prerenal azotemia results from Addison’s
disease. A particular caution is required in the manage-
ment of the patient who is already receiving dialysis.
Danger of hyperkalemia seems to be major discourage for
their prescription in those patients.
We have previously undertaken a cross-sectional stu-
dy in 194 maintenance HD patients and showed that 63
of them that received RAAS inhibitors did not differ in
kalemia in comparison with 131 patients without that
medication6. In our study we used ramipril, which had
major indication based on trial data for the following: a)
cardiovascular prevention (HOPE)7 b) heart failure, post-
myocardial infarction (AIRE)8 c) diabetic nephropathy
(MICRO-HOPE)9 d) chronic renal disease (REIN)10. The
results encouraged us to perform a prospective study on
kalemia change following prescription of ramipril in ESRD
treated with HD. We hypothesized that introduction of
ramipril treatment would not significantly increase serum
potassium concentration in maintenance HD patients.
Objective of the study was an examination of in-
creased risk of hyperkalemia in chronic hemodialysis pa-
tients upon blockade of renin-angiotensin system by an-
giotensin converting enzyme inhibitors. Endpoints in-
cluded significant change in kalemia and incidence of se-
vere hyperkalemia.
Subjects and Methods
Study included 28 patients (10 women, 18 men), mean
age 58±11 years, treated by maintenance HD for median
time 4.5 years (from 1 to 19 years) in Osijek University
Hospital Center, Osijek, Croatia. They suffered from
common basic renal diseases that cause ESRD (Table 1).
They received HD three times a week for 4 to 4.5h. Bicar-
bonate dialysis was applied in all patients. No change in
dialytic solution or in dialysators was done during the
study. Main inclusion criterion was potential cardiovas-
cular benefit from ACE inhibitor therapy, i.e. those with
left ventricular hypertrophy, diabetes mellitus, unregu-
lated arterial hypertension, chronic heart failure and his-
tory of myocardial infarction. Exclusion criteria were as
follows: current medication with RAAS inhibitor, chronic
or frequent hypotension (systolic blood pressure 100
mmHg or less, not only intradialytic) and predialysis
kalemia of 6 mmol/L and above that value, even only
once during the previous two-month regular check-ups
(since on maintenance dialysis).
Diagnosis of arterial hypertension was considered if
patient already had such diagnosis or was taking anti-
hypertensives. Twenty nine of total 194 patients receiv-
ing HD in the centre fulfilled the criteria and accepted
the proposed treatment with ramipril. They underwent
predialysis serum potassium concentration determina-
tion before the therapy introduction and again 1–3 mon-
ths afterwards, thrice in 7 days, respectively. Potassium
was determined by routine method in the hospital labo-
ratory, as usual, with caution to avoid artificial hyper-
kalemia. One patient dropped out of the study during a
run-in phase, due to hyperkalemia of 6 mmol/L in one of
the three predialytic potassium measurements before
the drug introduction. He was not included in the statis-
tical analysis. Predialytic blood pressure measurements
were recorded just before 6 consecutive HD sessions,
along with already scheduled potassium determination.
The measurement was done by nurse in supine position,
after at least 10 minutes rest. Mean arterial pressure
(MAP) was calculated according to the standard equa-
tion- diastolic + 1/3 (systolic-diastolic), for all measure-
ments. For three MAP values before ramipril introduc-
tion and 1–3 months afterwards mean MAP was calcu-
lated, respectively. That two meanMAP values were used
for statistical analysis. Mean potassium serum concen-
tration was calculated for three predialysis values before
the drug introduction and for three predialysis potas-
sium values 1–3 months afterwards, respectively. Those
two mean potassium values were used for statistical
analysis. Residual diuresis and other antihypertensive
medication were recorded. Anuria was considered when
daily urine output was less than 100 mL. Additional sub-
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Duration of chronic hemodialysis
(years)
median 4.5








































groups were analyzed divided according to daily urine
output of 500 mL and more or less than that. All patients
denied taking resins regularly. The patients were pre-
scribed small doses of ramipril (Tritace, Sanofi-Aventis
Group, Paris) 1.25, 2.5 or 5 mg upon conventional anti-
hypertensive therapy to achieve diastolic blood pressure
under 90 mmHg. Endpoints were change in kalemia and
incidence of severe hyperkalemia (6.0 mmol/L).
Statistics
Statistical analysis was performed using software
package SPSS 17.0 (SPSS inc, Chicago, IL, USA). De-
pending on the type of variable and normality of distribu-
tion, descriptive statistics used frequencies, means±SD
and median (range) to present the data. Potassium con-
centration distribution was normally distributed and
paired t-test was used for comparison analysis. Paired
t-test was although used for further examination of dif-
ferences between normally distributed variables throu-
ghout the study. p<0.05 was considered statistically sig-
nificant. For comparison between 2 independent samples
Mann-Whitney test was used because of small size of the
subgroups, irrespective of the distribution. Sample size
suffices for relevant statistical conclusion, while for min-
imal significant difference in serum potassium concen-
tration of 0.3 mmol/L and presumed standard deviation
in the difference in kalemia (according to our previous
study) of 0.4 mmol/L 12.5 pairs of observations is needed
(2´0.3/0.4 – Altman’s nomogram).
Results
One patient dropped out during a run-in phase of the
study because of hyperkalemia before ramipril introduc-
tion and twenty eight patients completed this prospec-
tive 3-month study. No worsening of anemia or other side
effects was found. Mean haemoglobin value before the
study was 104±10 g/L, and 104±8 g/L after 3 months
(t=0.383, p=0.705). There was no need to increase a dose
of erythropoietin. Nineteen patients in our study were
treated with erythropoietin in a median dose 4000 UI per
week (2000–8000 UI). Table 2 presents the values of
kalemia and MAP before and after introduction of ra-
mipril. Median dose of ramipril was 1.25 mg (21 patiens
were given a dose of 1.25 mg ramipril, 5 patients were
taking a dose of 2.5 mg ramipril and 2 patients were tak-
ing 5 mg ramipril). Mean serum concentration of potas-
sium was similar before and with ramipril treatment
(5.0±0.3 vs. 5.0±0.4mmol/L, p=0.269). Twelve patients
were anuric and they did not show any significant hy-
perkalemic changes compared with non-anuric patients
(Table 3). Most of the patients were taking other medica-
tion, including diuretics and beta blockers that could in-
terfere with potassium homeostasis. Fifteen patients had
hypertension and were taking antihypertensives. After 3
months on ramipril therapy mean arterial pressure was
not significantly changed compared to the basal values
(101±10 vs. 102±7 mmHg, p=0.691). Kalemia following
ramipril medication differed significantly in anuric pa-
tients (n=12) in comparison with those (n=16) with re-
sidual diuresis (median 4.8 mmol/L, min. 4.1, max. 5.4 vs
median 5.1 mmol/L, min. 4.4, max. 5.7, z=–2.021, p=
0.043), while the pretreatment values were not different.
Blood pressure between anuric and non-anuric patients
did not differ significantly both before and after ramipril
introduction. No difference in kalemia and blood pres-
sure was found between those excreting more than 500
mL of urine daily in comparison with patients with less
diuresis, neither before nor with ramipril therapy. Differ-
ence in serum potassium concentration and in blood
pressure before and following ramipril treatment was
not found between the patients taking diuretics, calcium
antagonists, beta blockers, or alpha blockers, and those
without such therapy, respectively. Nitrates were taken
by 9 patients and their blood pressure (MAP) before
ramipril introduction was statistically different than in
19 others (median 93, min. 88, max. 104 vs. median 103,
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TABLE 2





Serum potassium concentration (mmol/L) 5.0±0.3 5.0±0.4 1.129 0.269
Mean arterial pressure (mmHg) 101±10 102±7 –0.401 0.691
TABLE 3













Anuric (n=12) 5.1 (4.6–5.5) 4.8 (4.1–5.4) 100 (76–122) 103 (86–119)
With residual diuresis (n=16) 5.1 (4.2–5.5) 5.1 (4.4–5.7) 103 (88–129) 102 (94–110)
Mann-Whitney test value (z) –0.419 –2.021 –0.675 –0.116
p 0.698 0.043 0.500 0.909
min. 76, max. 129; z=–2.096, p=0.036). The difference
disappeared after ramipril introduction. Kalemia did not
differ between the subgroups of patients divided accord-
ing to the nitrates therapy before ramipril, but the val-
ues following ramipril therapy differed significantly (me-
dian 4.7 min. 4.3, max. 5.4 vs median 5.1, min.4.1, max.
5.7; z=–2.191, p=0.028). Table 4 shows values of kalemia
and MAP before and after ramipril introduction in the
subgroups of patients divided according to different med-
ications, as was stated in the preceding text.
Discussion
We conducted the prospective study to confirm the hy-
pothesis that ACE inhibitors would not affect kalemia in
maintenance dialysis patients. Indeed, serum potassium
did not increase with ramipril therapy, even though the
drug was known to induce hyperkalemia, particularly in
renal failure. Previous studies investigated effect of ACE
inhibitors on preservation of renal function and included
patients with earlier stages of renal dysfunction11–13.
Very few studies investigated treatment of hemodialyzed
patient with ACE inhibitors14. Woong found that neither
monotherapy (ACE inhibitors or ARB (angiotensin II re-
ceptor blocker)) nor combination therapy (ACE inhibitor
plus ARB) was associated with an additional risk of
hyperkalemia in patients on maintenance haemodialysis.
Different results were shown in the prospective study in
hemodialysis patients conducted by Knoll et al.15 They
found that the use of ACE inhibitors or angiotensin re-
ceptor blockers was associated with significantly higher
risk of hyperkalemia. Approximately 20% of patients ap-
proaching haemodialysis have diagnosis of heart failure
(HF)16. ACE inhibitors and beta-blockers have class I
recommendation for treatment of left ventricular sys-
tolic dysfunction according to the new therapeutic guide-
lines17. Limited data suggest that these agents are un-
derused in patients with ESRD. Roy et al. demonstrated
that only 25.5% of patients with ESRD and left ventricu-
lar dysfunction receive appropriate treatment18. The rea-
sons stated for not prescribing those medications were
»concern about adverse reactions». The common concern
is worsened hyperkalemia, which is rare but life threat-
ening adverse affect of ACEI. In our study serum potas-
sium level was not affected by ramipril treatment and
there were not episodes of severe hyperkalemia during
the study period. Serum potassium levels in the anuric
group of our patients were even lower than those in
non-anuric group. It could be explained by their better
compliance to dietary restrictions. The results could con-
tribute those of Wong, which showed that ACEI or ARB
therapy was safe in chronic HD patients, even with lower
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Beta blockers YES (n=17) 5.1 (4.6–5.5) 5.0 (4.1–5.7) 100 (76–129) 102 (89–119)
Beta blockers NO (n=11) 4.9 (4.2–5.3) 4.8 (4.3–5.6) 98 (92–122) 100 (93–110)
Mann-Whitney test value (z) –1.627 –0.965 –0.495 –0.118
p 0.111 0.353 0.643 0.926
Alfa blockers YES (n=21) 5.1 (4.2–5.5) 5.0 (4.1–5.6) 100 (76–129) 100 (89–119)
Alfa blockers NO (n=7) 5.3 (4.7–5.5) 4.8 (4.4–5.7) 100 (92–109) 106 (93–110)
Mann-Whitney test value (z) –1.915 –0.027 –0.053 –0.885
p 0.055 1.000 0.959 0.405
Diuretics YES (n=18) 5.1 (4.7–5.5) 5.1 (4.4–5.7) 99 (76–122) 99 (89–119)
Diuretics NO (n=10) 5.1 (4.2–5.5) 4.8 (4.1–5.4) 106 (88–129) 103 (94–110)
Mann-Whitney test value (z) –0.312 –1.847 –1.081 –0.528
p 0.759 0.064 0.286 0.621
Calcium antagonist YES (n=11) 5.1 (4.6–5.5) 4.8 (4.4–5.7) 100 (92–122) 100 (93–110)
Calcium antagonist NO (n=17) 5.1 (4.2–5.5) 4.9 (4.1–5.6) 100 (76–129) 102 (89–119)
Mann-Whitney test value (z) –0.354 –0.071 –0.354 –0.141
p 0.746 0.963 0.746 0.890
Nitrates YES (n=19) 5.1 (4.6–5.5) 4.7 (4.3–5.4) 103 (76–129) 103 (95–119)
Nitrates NO (n=9) 5.1 (4.2–5.4) 5.1 (4.1–5.7) 93 (88–104) 94 (89–110)
Mann-Whitney test value (z) –0.173 –2.191 –2.096 –1.921
p 0.885 0.028 0.036 0.055
kalemia upper normal referent value (5.5 mmol/L in
comparison with 6.0 mmol/L in our study). Patients on
ramipril treatment had not intolerable side effects. Ra-
mipril had not significant effect on patients’ hemoglobin
levels and there was no need to increase the dose of
erythropoietin. Due to several mechanisms of ACEI in-
terfering with erythropoiesis one could expect worsening
of anemia with ramipril, like in a study with enalapril19.
It is possible that the therapy required longer use of the
drug to express such effect. The group’s anaemia was at a
representative level for chronic hemodialyzed patients,
comparable to common state among such group of pa-
tients of the same size20. According to few reports on that
topic and with respect to our findings, it should be wise
to consider changing the guidelines or prescription rec-
ommendations by declaring that maintenance dialysis
should not present contraindication for ACEI treatment.
Careful control of potassium is necessary. It is the initial
attitude that should be changed. Those patients should
be considered for ACEI treatment and excluded if hyper-
kalemia was recorded. Those drugs should not be a priori
contraindicated. Diet prescriptions remain also manda-
tory, especially in the continental patients, shown to be of
greater body weight and worse dietary habits than their
maritime counterparts21. The effect on cardiac function
could be favorable. However, kalemia itself should always
limit their use if high values are determined. Limitations
of the study could include the number of the patients and
the duration of the study. However, we checked the sam-
ple size needed for testing our hypothesis and it turned
out that our group of patients suited to the number
needed, as it was aforementioned in the methods chapter.
Nevertheless, according to our experience ACE inhibi-
tors related hyperkalemia occurs short time after the in-
troduction of the medicine. Therefore, we considered 1
month after introduction of ramipril a sufficient period
for the drug induced hyperkalemia to ensue. However,
for anemia to worsen, the time could have been to short.
Conclusion
Kalemia in chronically hemodialyzed patient was not
affected by ramipril therapy. The results encourage the
use of small doses of ACE inhibitors in HD patients.
However, close potassium monitoring is mandatory.
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RIZIK POJAVE HIPERKALEMIJE UZ PRIMJENU RAMIPRILA U BOLESNIKA NA KRONI^NOJ
HEMODIJALIZI
S A @ E T A K
Primjena inhibitora konvertaze angiotenzina I (ACE inhibitora) u kroni~nom bubre`nom zatajenju ostvaruje osim
antihipertenzivnoga i povoljno za{titno djelovanje na funkciju bubrega i sr~ano`ilnog sustava. Unato~ poznatom povolj-
nom protektivnom djelovanju ACE inhibitori se nedovoljno primjenjuju u lije~enju bolesnika na kroni~nom programu
hemodijalize, prvenstveno zbog straha od pojave hiperkalemije. Vrlo su rijetka istra`ivanja u~inka blokade renin-an-
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giotenzin-aldosteronskog sustava (RAAS) na vrijednosti serumskog kalija u bolesnika na hemodijalizi. Istra`ivali smo
sigurnost primjene ramiprila u bolesnika na kroni~nom programu hemodijalize. Uklju~eno je 28 odraslih bolesnika sa
zavr{nim stupnjem kroni~nog bubre`nog zatajenja lije~enih ponavljanim hemodijalizama 3 puta tjedno u trajanju od 4
do 4,5 sata. Bolesnicima je propisan ramipril u dozi od 1,25 do 5 mg dnevno. Vrijednost serumskog kalija odre|ivana je 3
puta prije uvo|enja ramiprila, te ponovo uz ramipril nakon 1 do 3 mjeseca terapije. Nije na|ena statisti~ki zna~ajna
razlika u prosje~noj vrijednosti serumskog kalija prije i nakon uvo|enja ramiprila (5,0±0,3 vs. 5,0±0,4). Rezultati istra-
`ivanja pokazuju da je primjena ramiprila sigurna u bolesnika na kroni~nom programu hemodijalize uz upozorenje o
potrebi redovite kontrole serumskog kalija.
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